2013
Denosumab for the treatment of bisphosphonate-refractory hypercalcemia of malignancy (HCM).
Hu M, Glezerman I, Leboulleux S, Insogna K, Gucalp R, Misiorowski W, Yu B, Zorsky P, Tosi D, Bessudo A, Jaccard A, Tonini G, Wang H, Braun A, Jain R. Denosumab for the treatment of bisphosphonate-refractory hypercalcemia of malignancy (HCM). Journal Of Clinical Oncology 2013, 31: e20512-e20512. DOI: 10.1200/jco.2013.31.15_suppl.e20512.Peer-Reviewed Original ResearchBone resorptionDay 10RANK ligandTumor-induced bone resorptionUnexpected safety findingsSerious adverse eventsNew treatment optionsDenosumab initiationSubcutaneous denosumabPrimary endpointDurable responsesFirst doseMedian durationSafety findingsAdverse eventsComplete responseMedian timeSerum calciumTreatment optionsDenosumabDay 1CSC levelsDlMedianTreatment
2008
Orthopaedic Management Improves the Rate of Early Osteoporosis Treatment After Hip Fracture
Miki RA, Oetgen ME, Kirk J, Insogna KL, Lindskog DM. Orthopaedic Management Improves the Rate of Early Osteoporosis Treatment After Hip Fracture. Journal Of Bone And Joint Surgery 2008, 90: 2346-2353. PMID: 18978403, DOI: 10.2106/jbjs.g.01246.Peer-Reviewed Original ResearchConceptsPrimary care physiciansHip fractureRate of treatmentCare physiciansOsteoporosis managementOsteoporosis treatmentOrthopaedic surgeonsOsteoporosis clinicPercentage of patientsManagement of osteoporosisMost patientsPharmacologic treatmentOsteoporosis educationOrthopaedic managementOrthopaedic teamIntervention groupPatientsOsteoporosisPhysiciansSurgeonsMonthsTreatmentClinicLower ratesFractures
1997
Role of c‐Src in cellular events associated with colony‐stimulating factor‐1‐induced spreading in osteoclasts
Insogna K, Tanaka S, Neff L, Horne W, Levy J, Baron R. Role of c‐Src in cellular events associated with colony‐stimulating factor‐1‐induced spreading in osteoclasts. Molecular Reproduction And Development 1997, 46: 104-108. PMID: 8981371, DOI: 10.1002/(sici)1098-2795(199701)46:1<104::aid-mrd16>3.0.co;2-2.BooksMeSH KeywordsActininAnimalsBone MarrowBone Marrow CellsCalcitriolCell SizeCells, CulturedCytoskeletonFemaleHumansMacrophage Colony-Stimulating FactorMiceMicroscopy, ConfocalOsteoblastsOsteoclastsOsteoporosisPhosphatidylinositol 4,5-DiphosphatePhosphorylationProtein Processing, Post-TranslationalProto-Oncogene Proteins pp60(c-src)RatsSignal TransductionConceptsOsteoclast-like cellsNeonatal rat osteoclastsRat osteoclastsCSF-1 treatmentMonoclonal antibodiesC-fmsCSF-1C-SrcCellular eventsWestern blot analysisTime-dependent increaseMurine bone marrowBasal abnormalitiesBone marrowConfocal microscopic studiesPIP2 contentSignificant doseReceptor tyrosine kinasesOsteoclastsTyrosine kinase activityC-Src kinase activityCell-signaling eventsTargeted disruptionTreatmentIntrinsic tyrosine kinase activity
1996
Boning Up on Estrogen: New Options, New Concerns
Insogna K, Concato J, Henrich J. Boning Up on Estrogen: New Options, New Concerns. JAMA 1996, 276: 1430-1432. DOI: 10.1001/jama.1996.03540170074037.Peer-Reviewed Original ResearchHormone replacement therapyPostmenopausal osteoporosisOral hormone replacement therapyRegular uterine bleedingInitiation of treatmentLong-term adherenceAlternative regimenEstrogen replacementPostmenopausal womenUterine bleedingProgestational agentsIntermittent administrationBone lossReplacement therapyOnly drugBone breakdownFracture ratesEstrogenWomenOsteoporosisDaily useNew optionsRecent studiesTreatmentBleeding
1989
Trichlormethiazide and Oral Phosphate Therapy in Patients with Absorptive Hypercalciuria
Insogna K, Ellison A, Burtis W, Sartori L, Lang R, Broadus A. Trichlormethiazide and Oral Phosphate Therapy in Patients with Absorptive Hypercalciuria. Journal Of Urology 1989, 141: 269-273. PMID: 2913343, DOI: 10.1016/s0022-5347(17)40737-3.Peer-Reviewed Original ResearchConceptsOral phosphate therapyDihydroxyvitamin D levelsAbsorptive hypercalciuriaUrinary calciumParathyroid functionPhosphate therapyPhosphate administrationD levelsOral phosphate administrationRenal phosphate thresholdTreatment urinary calciumStudy 36 patientsPre-treatment valuesTrichlormethiazide treatmentCalcium excretionDihydroxyvitamin DBiochemical abnormalitiesSecond drugPharmacological meansStudy subjectsHypercalciuriaPatientsTherapyPer cent decreaseTreatment